Imipramine and amitriptyline ameliorate the rotenone model of Parkinson’s disease in rats
Highlights • Imipramine and amitriptyline abate neurodegeneration in Parkinson’s disease. • Modulation of monoamines and neurotrophin levels contributes to the neuroprotection. • Antioxidant and anti-inflammatory properties underlie the drugs’ protective effects.
Gespeichert in:
| Veröffentlicht in: | Neuroscience 2016-09, Vol.332, p.26-37 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 37 |
|---|---|
| container_issue | |
| container_start_page | 26 |
| container_title | Neuroscience |
| container_volume | 332 |
| creator | Kandil, Esraa A Abdelkader, Noha F El-Sayeh, Bahia M Saleh, Samira |
| description | Highlights • Imipramine and amitriptyline abate neurodegeneration in Parkinson’s disease. • Modulation of monoamines and neurotrophin levels contributes to the neuroprotection. • Antioxidant and anti-inflammatory properties underlie the drugs’ protective effects. |
| doi_str_mv | 10.1016/j.neuroscience.2016.06.040 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1811875888</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0306452216302792</els_id><sourcerecordid>1811875888</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-f12fb3c9da7ee5a67728a11cae90c2e57489f6975e69d995d80b5009f1ce41943</originalsourceid><addsrcrecordid>eNqNkc2KFDEUhYMoTs_oK0hw5aba_FYSF4KMjg4MKKgrFyGd3ML0VCVtUiX0ztfw9XwS03Yr4spwIeFyzr3kOwg9pmRNCe2fbtcJlpKrj5A8rFnrrUkrQe6gFdWKd0oKcRetCCd9JyRjZ-i81i1pRwp-H50xxXtJFV-hT9dT3BU3xQTYpYDbay5xN-_HX50JxpiLmwHPnwGXPEPKrT_lACPOA37nym1MNacf375XHGIFVwHHhJunPkD3BjdWeHi6L9DHq1cfLt90N29fX1--uOm86PXcDZQNG-5NcApAul4pph2l3oEhnoFUQpuhN0pCb4IxMmiykYSYgXoQ1Ah-gZ4c5-5K_rJAne0Uq4dxdAnyUi3VtFGRWusmfXaU-savFhjsrsTJlb2lxB7g2q39G649wLWklSDN_Oi0Z9lMEP5Yf9NsgpdHAbTffo1Q7GlMiAX8bEOO_7fn-T9jfEsjejfewh7qNi8lNZ6W2sosse8PMR9Spj0nTBnGfwJWJqjz</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1811875888</pqid></control><display><type>article</type><title>Imipramine and amitriptyline ameliorate the rotenone model of Parkinson’s disease in rats</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Kandil, Esraa A ; Abdelkader, Noha F ; El-Sayeh, Bahia M ; Saleh, Samira</creator><creatorcontrib>Kandil, Esraa A ; Abdelkader, Noha F ; El-Sayeh, Bahia M ; Saleh, Samira</creatorcontrib><description>Highlights • Imipramine and amitriptyline abate neurodegeneration in Parkinson’s disease. • Modulation of monoamines and neurotrophin levels contributes to the neuroprotection. • Antioxidant and anti-inflammatory properties underlie the drugs’ protective effects.</description><identifier>ISSN: 0306-4522</identifier><identifier>EISSN: 1873-7544</identifier><identifier>DOI: 10.1016/j.neuroscience.2016.06.040</identifier><identifier>PMID: 27365173</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>amitriptyline ; Amitriptyline - pharmacology ; Animals ; Anti-Inflammatory Agents, Non-Steroidal - pharmacology ; Antioxidants - pharmacology ; Antiparkinson Agents - pharmacology ; Dopaminergic Neurons - drug effects ; Dopaminergic Neurons - metabolism ; Dopaminergic Neurons - pathology ; imipramine ; Imipramine - pharmacology ; Immunohistochemistry ; Male ; Microglia - drug effects ; Microglia - metabolism ; Microglia - pathology ; Neurology ; neuroprotection ; Neuroprotective Agents - pharmacology ; Oxidative Stress - drug effects ; Oxidative Stress - physiology ; Parkinsonian Disorders - drug therapy ; Parkinsonian Disorders - pathology ; Parkinsonian Disorders - physiopathology ; Parkinson’s disease ; Rats, Wistar ; Rotarod Performance Test ; Rotenone ; Substantia Nigra - drug effects ; Substantia Nigra - metabolism ; Substantia Nigra - pathology</subject><ispartof>Neuroscience, 2016-09, Vol.332, p.26-37</ispartof><rights>IBRO</rights><rights>2016 IBRO</rights><rights>Copyright © 2016 IBRO. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-f12fb3c9da7ee5a67728a11cae90c2e57489f6975e69d995d80b5009f1ce41943</citedby><cites>FETCH-LOGICAL-c468t-f12fb3c9da7ee5a67728a11cae90c2e57489f6975e69d995d80b5009f1ce41943</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.neuroscience.2016.06.040$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27365173$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kandil, Esraa A</creatorcontrib><creatorcontrib>Abdelkader, Noha F</creatorcontrib><creatorcontrib>El-Sayeh, Bahia M</creatorcontrib><creatorcontrib>Saleh, Samira</creatorcontrib><title>Imipramine and amitriptyline ameliorate the rotenone model of Parkinson’s disease in rats</title><title>Neuroscience</title><addtitle>Neuroscience</addtitle><description>Highlights • Imipramine and amitriptyline abate neurodegeneration in Parkinson’s disease. • Modulation of monoamines and neurotrophin levels contributes to the neuroprotection. • Antioxidant and anti-inflammatory properties underlie the drugs’ protective effects.</description><subject>amitriptyline</subject><subject>Amitriptyline - pharmacology</subject><subject>Animals</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</subject><subject>Antioxidants - pharmacology</subject><subject>Antiparkinson Agents - pharmacology</subject><subject>Dopaminergic Neurons - drug effects</subject><subject>Dopaminergic Neurons - metabolism</subject><subject>Dopaminergic Neurons - pathology</subject><subject>imipramine</subject><subject>Imipramine - pharmacology</subject><subject>Immunohistochemistry</subject><subject>Male</subject><subject>Microglia - drug effects</subject><subject>Microglia - metabolism</subject><subject>Microglia - pathology</subject><subject>Neurology</subject><subject>neuroprotection</subject><subject>Neuroprotective Agents - pharmacology</subject><subject>Oxidative Stress - drug effects</subject><subject>Oxidative Stress - physiology</subject><subject>Parkinsonian Disorders - drug therapy</subject><subject>Parkinsonian Disorders - pathology</subject><subject>Parkinsonian Disorders - physiopathology</subject><subject>Parkinson’s disease</subject><subject>Rats, Wistar</subject><subject>Rotarod Performance Test</subject><subject>Rotenone</subject><subject>Substantia Nigra - drug effects</subject><subject>Substantia Nigra - metabolism</subject><subject>Substantia Nigra - pathology</subject><issn>0306-4522</issn><issn>1873-7544</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc2KFDEUhYMoTs_oK0hw5aba_FYSF4KMjg4MKKgrFyGd3ML0VCVtUiX0ztfw9XwS03Yr4spwIeFyzr3kOwg9pmRNCe2fbtcJlpKrj5A8rFnrrUkrQe6gFdWKd0oKcRetCCd9JyRjZ-i81i1pRwp-H50xxXtJFV-hT9dT3BU3xQTYpYDbay5xN-_HX50JxpiLmwHPnwGXPEPKrT_lACPOA37nym1MNacf375XHGIFVwHHhJunPkD3BjdWeHi6L9DHq1cfLt90N29fX1--uOm86PXcDZQNG-5NcApAul4pph2l3oEhnoFUQpuhN0pCb4IxMmiykYSYgXoQ1Ah-gZ4c5-5K_rJAne0Uq4dxdAnyUi3VtFGRWusmfXaU-savFhjsrsTJlb2lxB7g2q39G649wLWklSDN_Oi0Z9lMEP5Yf9NsgpdHAbTffo1Q7GlMiAX8bEOO_7fn-T9jfEsjejfewh7qNi8lNZ6W2sosse8PMR9Spj0nTBnGfwJWJqjz</recordid><startdate>20160922</startdate><enddate>20160922</enddate><creator>Kandil, Esraa A</creator><creator>Abdelkader, Noha F</creator><creator>El-Sayeh, Bahia M</creator><creator>Saleh, Samira</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7TK</scope></search><sort><creationdate>20160922</creationdate><title>Imipramine and amitriptyline ameliorate the rotenone model of Parkinson’s disease in rats</title><author>Kandil, Esraa A ; Abdelkader, Noha F ; El-Sayeh, Bahia M ; Saleh, Samira</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-f12fb3c9da7ee5a67728a11cae90c2e57489f6975e69d995d80b5009f1ce41943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>amitriptyline</topic><topic>Amitriptyline - pharmacology</topic><topic>Animals</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</topic><topic>Antioxidants - pharmacology</topic><topic>Antiparkinson Agents - pharmacology</topic><topic>Dopaminergic Neurons - drug effects</topic><topic>Dopaminergic Neurons - metabolism</topic><topic>Dopaminergic Neurons - pathology</topic><topic>imipramine</topic><topic>Imipramine - pharmacology</topic><topic>Immunohistochemistry</topic><topic>Male</topic><topic>Microglia - drug effects</topic><topic>Microglia - metabolism</topic><topic>Microglia - pathology</topic><topic>Neurology</topic><topic>neuroprotection</topic><topic>Neuroprotective Agents - pharmacology</topic><topic>Oxidative Stress - drug effects</topic><topic>Oxidative Stress - physiology</topic><topic>Parkinsonian Disorders - drug therapy</topic><topic>Parkinsonian Disorders - pathology</topic><topic>Parkinsonian Disorders - physiopathology</topic><topic>Parkinson’s disease</topic><topic>Rats, Wistar</topic><topic>Rotarod Performance Test</topic><topic>Rotenone</topic><topic>Substantia Nigra - drug effects</topic><topic>Substantia Nigra - metabolism</topic><topic>Substantia Nigra - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kandil, Esraa A</creatorcontrib><creatorcontrib>Abdelkader, Noha F</creatorcontrib><creatorcontrib>El-Sayeh, Bahia M</creatorcontrib><creatorcontrib>Saleh, Samira</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Neurosciences Abstracts</collection><jtitle>Neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kandil, Esraa A</au><au>Abdelkader, Noha F</au><au>El-Sayeh, Bahia M</au><au>Saleh, Samira</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Imipramine and amitriptyline ameliorate the rotenone model of Parkinson’s disease in rats</atitle><jtitle>Neuroscience</jtitle><addtitle>Neuroscience</addtitle><date>2016-09-22</date><risdate>2016</risdate><volume>332</volume><spage>26</spage><epage>37</epage><pages>26-37</pages><issn>0306-4522</issn><eissn>1873-7544</eissn><abstract>Highlights • Imipramine and amitriptyline abate neurodegeneration in Parkinson’s disease. • Modulation of monoamines and neurotrophin levels contributes to the neuroprotection. • Antioxidant and anti-inflammatory properties underlie the drugs’ protective effects.</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>27365173</pmid><doi>10.1016/j.neuroscience.2016.06.040</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0306-4522 |
| ispartof | Neuroscience, 2016-09, Vol.332, p.26-37 |
| issn | 0306-4522 1873-7544 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1811875888 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | amitriptyline Amitriptyline - pharmacology Animals Anti-Inflammatory Agents, Non-Steroidal - pharmacology Antioxidants - pharmacology Antiparkinson Agents - pharmacology Dopaminergic Neurons - drug effects Dopaminergic Neurons - metabolism Dopaminergic Neurons - pathology imipramine Imipramine - pharmacology Immunohistochemistry Male Microglia - drug effects Microglia - metabolism Microglia - pathology Neurology neuroprotection Neuroprotective Agents - pharmacology Oxidative Stress - drug effects Oxidative Stress - physiology Parkinsonian Disorders - drug therapy Parkinsonian Disorders - pathology Parkinsonian Disorders - physiopathology Parkinson’s disease Rats, Wistar Rotarod Performance Test Rotenone Substantia Nigra - drug effects Substantia Nigra - metabolism Substantia Nigra - pathology |
| title | Imipramine and amitriptyline ameliorate the rotenone model of Parkinson’s disease in rats |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T20%3A02%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Imipramine%20and%20amitriptyline%20ameliorate%20the%20rotenone%20model%20of%20Parkinson%E2%80%99s%20disease%20in%20rats&rft.jtitle=Neuroscience&rft.au=Kandil,%20Esraa%20A&rft.date=2016-09-22&rft.volume=332&rft.spage=26&rft.epage=37&rft.pages=26-37&rft.issn=0306-4522&rft.eissn=1873-7544&rft_id=info:doi/10.1016/j.neuroscience.2016.06.040&rft_dat=%3Cproquest_cross%3E1811875888%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1811875888&rft_id=info:pmid/27365173&rft_els_id=1_s2_0_S0306452216302792&rfr_iscdi=true |